AgingResearch.NewsJoin free

Suzhou Vincentage Pharma

CompanyChina

Suzhou Vincentage Pharma develops one asset, in phase 2 (VCT220 in type 2 diabetes). Mostly small molecule acting on GLP1R; based in China.

1
Asset
Furthest stage
Phase 2
0
Trials
3
Signals

Pipeline

1

  • VCT220

    Oral GLP-1 receptor agonist for obesity and overweight

    Phase 2, Small molecule, GLP1R, type 2 diabetes, obesity

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Signals6
  • Similar companies6

Papers

Intelligence